The Regulator

CMS missed its October 31 date to tell states what they will get in year two of the $50 billion Rural Health Transformation Program, and says the competitive portion is delayed. According to KFF Health News, an October 30 mass email from Alina Czekai, director of the Centers for Medicare & Medicaid Services (CMS) Office of Rural Health Transformation, said each state’s second-year base funding of $100 million is available, but officials “discovered an additional administrative process requirement” and the competitive portion is on hold, with no new date. Who it hits: state health agencies, and the rural hospitals, clinics and vendors that wait on state subgrants. So what: the program is $10 billion a year for five years, year-one awards ran from $147 million to $281 million per state, and by our arithmetic anything above the $100 million base rides on the delayed portion. Budget revisions tied to the new allocations are due back to CMS by November 30. Confidence: Med. CMS declined to comment to KFF, and we found no CMS notice or copy of the email. Sources: KFF Health News report on the funding delay.

CMS gave Arkansas six more months of its private-insurance Medicaid expansion, ARHOME, not the two years the state asked for. Arkansas Human Services Secretary Janet Mann asked on August 5 for a two-year extension after CMS found the pending renewal would not meet the budget neutrality rules that take effect next year under the 2025 federal budget law. Local reporting says the program now runs to June 30, 2027. Who it hits: Arkansans covered through ARHOME, and the insurer Centene, which the state says ends its ARHOME participation in 2027. So what: the state says no one has to act now and expansion is not ending, but a new delivery model must be built and approved through the 2027 legislative session, and penalties for missing the work and community engagement requirements start January 1, 2027, for adults 19 to 64. Confidence: Med. We could not find the CMS approval letter, so the end date rests on local reports. Sources: KATV report on the CMS approval, Arkansas Department of Human Services release on the August request. Supplemental: El Dorado News-Times report.

FDA formally classified artificial intelligence software for reading cervical cancer screening slides, and prognostic software for mild cognitive impairment, into class II. The Food and Drug Administration (FDA) orders, published in the Federal Register November 5 and effective that day, put the digital cervical cytology slide imaging system with an AI algorithm, the prognostic assessment software for mild cognitive impairment, and a wearable vibration device for orthopedic use into class II, which means special controls instead of the most demanding premarket approval. Who it hits: makers of AI pathology and neurology software and orthopedic wearables. So what: FDA says the classifications applied from the original authorizations, on January 31, January 11 and January 12, 2024, so the orders formalize decisions already in use and set the controls that later competitors will be measured against. No comment period applies and no costs are stated. Confidence: High on the classifications, which come from the Federal Register. Sources: Federal Register FDA order 2026-22593, Federal Register FDA order 2026-22590, Federal Register FDA order 2026-22589.

FDA published a discussion paper on robotic medical devices that act autonomously or by remote teleoperation, and is taking comments until January 5, 2027. The paper covers devices that perform diagnostic, therapeutic or rehabilitative tasks on the body, in surgical and non-surgical uses, and lays out four topics: terminology, benefit and risk of autonomous capabilities, benefit and risk of remote teleoperation, and risk mitigations. Who it hits: surgical robotics makers, imaging and rehabilitation robot developers, and the hospitals that would buy them. So what: FDA says the paper is for discussion only, not draft or final guidance, and states no regulatory expectations, so it is an early signal and not a rule; comments go to docket FDA-2026-N-13135. FDA’s calendar also lists a related public workshop that appears to be set for December 2, 2026. Confidence: High on the paper and deadline, which come from FDA; Low on the workshop date, which we read only from a listing title. Sources: FDA discussion paper page, FDA Center for Devices and Radiological Health news page.